Table 2: Relation between clinicopathological variables and clinical response to methotrexate.

CharacteristicResponse
( )
Nonresponse
( )
value

Patient-related
Male, (%)19 (51.4)18 (48.6)Reference
Female, (%)86 (43.9)110 (56.1)0.402
 Premenopausal, (%)39 (39.0)61 (61.0)Reference
 Postmenopausal, (%)47 (49.0)49 (51.0)0.160
Age, mean ± SD, years <0.001
BMI, median (IQR), Kg/m226.2 (18.5–43.1)26.3 (18.4–38.9)0.574
Noncurrent smoker*, (%)83 (41.3)118 (58.7)Reference
Current smoker, (%) 22 (68.8)10 (31.2)
 NPY**, median (IQR)20.1 (1.5–120.0)14.0 (0.8–40.0)0.269
Noncomorbidity, (%)51 (47.7)56 (52.3)Reference
Comorbidity***, (%)54 (42.9)72 (57.1)0.462

Disease-related
Diagnosis age, mean ± SD, years 0.081
Disease duration, median (IQR), years8.0 (1.0–53.0)8.0 (0.5–38.0)0.164
RF negative, (%)42 (41.2)60 (58.8)Reference
RF positive, (%)63 (48.1)68 (51.9)0.293
Anti-CCP negative, (%)35 (60.3)23 (39.7)Reference
Anti-CCP positive, (%)70 (40.0)105 (60.0)
ANAs negative, (%)83 (49.7)84 (50.3)Reference
ANAs positive, (%)22 (33.3)44 (66.7)
DAS28, mean ± SD 0.089
Individual variables—DAS28
 TJC (out of 28), median (IQR) 3.0 (0.0–27.0)5.0 (0.0–20.0)0.007
 SJC (out of 28), median (IQR)2.0 (0.0–24.0)4.0 (0.0–23.0)0.008
 ESR, median (IQR), minutes (1st hour) 19.0 (1.0–88.0)17.0 (1.0–92.0)0.509
 Global health on VAS, median (IQR) 47.0 (0.0–100.0)49.0 (0.0–100.0)0.516
 HAQ score, median (IQR)1.1 (0.0–2.9)1.5 (0.0–2.6)0.006

Treatment-related
Symptomatic
 Noncorticosteroids, (%) 21 (46.7)24 (53.3)Reference
 Corticosteroids, (%) 84 (44.7)104 (55.3)0.810
 Non-NSAIDs, (%)41 (65.1)22 (34.9)Reference
 NSAIDs, (%)64 (37.6)106 (62.4)
Supplements
 Folic acid nonregular users, (%)52 (45.2)63 (54.8)Reference
 Folic acid regular users, (%) 53 (44.9)65 (55.1)0.963
Methotrexate administration characteristics
 Dose, median (IQR), mg/week15.0 (2.5–25.0)20.0 (7.5–25.0)<0.001
 Treatment duration, median (IQR), months28.0 (6.0–230.0)29.0 (6.0–209.0)0.204
Per os administration route, (%)83 (41.3)118 (58.7)Reference
 Subcutaneous administration route, (%)22 (68.8)10 (31.2)

Noncurrent smokers include the never smokers and the ex-smokers.
**NPY = (number of cigarettes smoked per day × number of years smoking)/20.
***Comorbidity was defined as the presence of diabetes mellitus, hypertension, dyslipidemia, and/or cardiac disorders beyond rheumatoid arthritis.
Drugs coadministered with methotrexate when clinical response to methotrexate was recorded.
value < 0.05 is considered to be of statistical significance (highlighted in bold).
aOR = 0.32, 95% CI: 0.14–0.71. bOR = 2.28, 95% CI: 1.24–4.19. cOR = 1.98, 95% CI: 1.09–3.58. dOR = 3.09, 95% CI: 1.69–5.65. eOR = 0.32, 95% CI: 0.14–0.71.
ANAs: antinuclear antibodies; anti-CCP: anti-cyclic citrullinated peptide; BMI: body mass index; DAS28: disease activity score 28; ESR: erythrocyte sedimentation rate; HAQ: health assessment questionnaire; IQR: interquartile range; NPY: number of pack years; NSAIDs: nonsteroidal anti-inflammatory drugs; RF: rheumatoid factor; SD: standard deviation; SJC: swollen joints count; TJC: tender joints count; VAS: visual analog scale.